Fulminant Hepatic Failure with Hepatitis B Virus Reactivation after Rituximab Treatment in a Patient with Resolved Hepatitis B / 대한소화기학회지
The Korean Journal of Gastroenterology
;
: 266-269, 2010.
Article
Dans Coréen
| WPRIM
| ID: wpr-213920
ABSTRACT
It is well known that the reactivation of hepatitis B virus (HBV) may occur as an acute hepatitis after chemotherapy or immunosuppressive therapy. Although most of these cases have been reported in HBsAg-positive patients, there have been a few reports of HBV reactivation in HBsAg-negative patients. There have been concerns for the need to screen the reactivation as well as anti-viral prophylaxis in HBsAg-negative patients with possible HBV occult infection who are planning to undergo chemotherapy or immunosuppressive therapy. Rituximab, an anti-CD20 monoclonal antibody, is effective in the treatment of non-Hodgkin's lymphoma. However, rituximab can affect the immunity against HBV, consequently increasing viral replication. In fact, there have been reports of HBV reactivation after treatment with rituximab. Here, we report a case of HBV reactivation following rituximab plus systemic chemotherapy in diffuse large B cell lymphoma patient who was HBsAg negative, anti-HBs positive, and anti-HBc positive, ultimately leading to treatment-unresponsive fulminant hepatic failure.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Antiviraux
/
Récidive
/
ADN viral
/
Virus de l'hépatite B
/
Lymphome B diffus à grandes cellules
/
Défaillance hépatique aigüe
/
Guanine
/
Hépatite B
/
Anticorps monoclonaux
/
Antinéoplasiques
Limites du sujet:
Adulte très âgé
/
Femelle
/
Humains
langue:
Coréen
Texte intégral:
The Korean Journal of Gastroenterology
Année:
2010
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS